Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma

NCT00052156 is registered in ClinicalTrials.gov with CancerVax Corporation as lead sponsor.

NCT NCT00052156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00052156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma
Lead sponsor
CancerVax Corporation
Phase
Phase 3
Overall status
Unknown status
Start date
Not reported
Completion date
Not reported
Enrollment
670
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma